Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Aug 28;15:608. doi: 10.1186/s12885-015-1605-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Djokovic et al. 2015

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — Dll4 allele deletion affects VEGF/VEGFR signaling and the regulators of vascular smooth muscle cell recruitment. a Average serum level of VEGF, VEGFR1, VEGFR2 measured by ELISA and VEGFR2/VEGFR1 (R2/R1) ratio in WT and Dll4^+/− mice. Between two experimental groups, only VEGFR2/VEGFR1 ratio (R2/R1) differs with statistical significance. b VEGFR2 immunostaining showing increased expression of this VEGF-A receptor in Dll4^+/− vs. control tumors. c Differential gene expression in WT vs. Dll4^+/− papillomas determined by quantitative RT-PCR analyses. d Double PECAM/PDGFR-β immunostaining showing reduced PDGFR-β+ vascular coverage and indicating reduced Pdgfr-β expression in the vasculature of Dll4^+/− vs. WT papillomas